Latest News and Press Releases

SYDNEY, AUSTRALIA--(Marketwire - September 20, 2010) -  Pharmaceutical development company, Novogen Limited (ASX: NRT) (NASDAQ: NVGN) has appointed three new Directors. Of the three...

SYDNEY, AUSTRALIA--(Marketwire - June 18, 2010) - Novogen Limited's subsidiary, Marshall Edwards, Inc. (NASDAQ: MSHL), has announced today the appointment of Mr. Thomas Zech as its CFO and Company...

SAN DIEGO, CA--(Marketwire - June 17, 2010) -  Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today...

SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 1, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...

SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 26, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...

SYDNEY, AUSTRALIA--(Marketwire - March 31, 2010) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) advises that it has entered into new executive service agreements with its seven most senior executives. ...

NEW CANAAN, CT--(Marketwire - March 31, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL) (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...

SYDNEY, AUSTRALIA--(Marketwire - February 8, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL) announced that Christopher Naughton had resigned as a member of the Board of Directors effective February 5,...

NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - April 20, 2009) - Data presented yesterday at the Annual Meeting of the American Association for Cancer Research in Denver has demonstrated that...

NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - April 14, 2009) - Marshall Edwards, Inc., (NASDAQ: MSHL) today announced that it will be undertaking an un-blinded analysis of the data from its...